This may well explain the efficacy of HDAC inhibitors in the treatment of TCR signaling-driven T cell lymphoma or the attenuation of TCR signaling observed in animal models of certain autoimmune diseases40,41. This evidence concerns the gene HDAC9 and T-cell non-Hodgkin lymphoma.